Skip to main content

Legal Action Being Taken Over Compounded Versions of Mounjaro

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

WEDNESDAY, Sept. 20, 2023 -- Another diabetes drug maker is taking legal action against businesses in several states, alleging that they are "fraudulently claiming" that their compounded products are the same as its medication.

This time, it is Eli Lilly suing certain medical spas, wellness centers, and compounding pharmacies over its medication Mounjaro. The medication contains the active ingredient tirzepatide and is approved by the U.S. Food and Drug Administration to treat type 2 diabetes. The company sells Mounjaro only in prefilled single-dose pens.

The lawsuits, filed Tuesday, are meant to stop the other companies from "the unlawful marketing and sale of non-FDA approved compounded products." In a statement issued Tuesday, the company said: "Lilly cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not our own branded product. These entities should be stopped from providing drug products in violation of consumer protection laws, particularly where they promise their patients that their drugs offer the same safety profile and clinical benefits as Mounjaro."

In June, Novo Nordisk sued businesses for making compounded versions of semaglutide, which is used in its type 2 diabetes drugs Ozempic and Rybelsus. The medication is also used to treat obesity under the brand name Wegovy. In its cases, Novo Nordisk has asked the companies to "cease and desist from false advertising, trademark infringement, and/or unlawful sales of non-FDA approved compounded products claiming to contain semaglutide."

Eli Lilly said these compounded versions can cause "potentially serious health risks," adding that "products claiming to contain tirzepatide that are made and/or distributed by compounding pharmacies or distributed by counterfeit sources have not been reviewed by the U.S. FDA or global regulatory agencies for safety, quality or efficacy."

People have reported adverse events from compounded semaglutide, according to the FDA. The agency has said patients "should not use a compounded drug if an approved drug is available." However, Mounjaro has been on the agency's drug shortages list since last year, along with Ozempic and Wegovy. "When a drug is in shortage, compounders may be able to prepare a compounded version of that drug if they meet certain requirements of the Federal Food, Drug, and Cosmetic (FD&C) Act," the FDA said.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults

FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

Weight Navigation Program Boosts Use of Weight Management Treatments

FRIDAY, May 31, 2024 -- A primary care-based weight navigation program (WNP) is feasible and associated with greater use of weight management treatments (WMT) and weight loss...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.